Search

Your search keyword '"VanVeldhuisen P"' showing total 10 results
Start Over Author "VanVeldhuisen P" Journal transplantation
10 results on '"VanVeldhuisen P"'

1. TWO YEAR FOLLOWUP OF A RANDOMIZED MULTICENTER KIDNEY TRANSPLANT STUDY COMPARING TACROLIMUS(PG)+AZATHIOPRINE(AZA) VS. CYCLOSPORINE(NEORAL)+MYCOPHENOLATE MOFETIL(MMF) VS. TACROLIMUS+MMF.

Author

Gonwa, Thomas A., primary, Johnson, C., additional, Ahsan, N., additional, Halloran, P., additional, Stegall, M., additional, Hardy, M., additional, Metzger, R., additional, Shield, C., additional, Rocher, L., additional, Scandling, J., additional, Sorensen, J., additional, Mulloy, L., additional, Light, J., additional, Corwin, C., additional, Danovitch, G., additional, Wachs, M., additional, VanVeldhuisen, P., additional, Salm, K., additional, Tolzman, D., additional, Scotellaro, P., additional, and Fitzsimmons, W., additional

Published
2000
Full Text
View/download PDF

2. Randomized trial of tacrolimus mycophenolate mofetil or azathioprine versus cyclosporine mycophenolate mofetil after cadaveric kidney transplantation results at three years

Author

Gonwa, Thomas, Johnson, Christopher, Ahsan, Nasimul, Alfrey, Edward J., Halloran, Philip, Stegall, Mark, Hardy, Mark, Metzger, Robert, Shield, Charles, Rocher, Leslie, Scandling, John, Sorensen, John, Mulloy, Laura, Light, Jimmy, Corwin, Claudia, Danovitch, Gabriel, Wachs, Michael, VanVeldhuisen, Paul, Leonhardt, Maryanne, and Fitzsimmons, William E.

Abstract

Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) mycophenolate mofetil (MMF), TAC azathioprine (AZA), or cyclosporine (Neoral; CsA) MMF. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function (DGF). Patients were followed-up for 3 years.

Published
2003
Full Text
View/download PDF

3. RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION RESULTS AT 2 YEARS1

Author

Ahsan, Nasimul, Johnson, Christopher, Gonwa, Thomas, Halloran, Philip, Stegall, Mark, Hardy, Mark, Metzger, Robert, Shield, Charles, Rocher, Leslie, Scandling, John, Sorensen, John, Mulloy, Laura, Light, Jimmy, Corwin, Claudia, Danovitch, Gabriel, Wachs, Michael, VanVeldhuisen, Paul, Salm, Kim, Tolzman, Diane, and Fitzsimmons, William E.

Abstract

A previous report described the 1-year results of a prospective, randomized trial designed to investigate the optimal combination of immunosuppressants in kidney transplantation. Recipients of first cadaveric kidney allografts were treated with tacrolimusmycophenolate mofetil (MMF), cyclosporine oral solution (modified) (CsA)MMF, or tacrolimusazathioprine (AZA). Results at 1 year revealed that optimal efficacy and safety were achieved with a regimen containing tacrolimusMMF. The present report describes results at 2 years.

Published
2001

4. RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2

Author

Johnson, Christopher, Ahsan, Nasimul, Gonwa, Thomas, Halloran, Philip, Stegall, Mark, Hardy, Mark, Metzger, Robert, Shield, Charles, Rocher, Leslie, Scandling, John, Sorensen, John, Mulloy, Laura, Light, Jimmy, Corwin, Claudia, Danovitch, Gabriel, Wachs, Michael, VanVeldhuisen, Paul, Salm, Kim, Tolzman, Diane, and Fitzsimmons, William E.

Abstract

Our clinical trial was designed to investigate the optimal combination of immunosuppressants for renal transplantation.

Published
2000

10. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

Author

Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Leonhardt M, and Fitzsimmons WE

Subjects
Acute Disease, Cadaver, Creatinine blood, Drug Therapy, Combination, Florida, Follow-Up Studies, Graft Survival immunology, Humans, Hyperglycemia epidemiology, Kidney Transplantation mortality, Kidney Transplantation physiology, Mycophenolic Acid analogs & derivatives, Postoperative Complications epidemiology, Probability, Racial Groups, Survival Analysis, Time Factors, Tissue Donors, Azathioprine therapeutic use, Cyclosporine therapeutic use, Graft Rejection epidemiology, Kidney Transplantation immunology, Mycophenolic Acid therapeutic use, Tacrolimus therapeutic use
Abstract

Methods: Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), or cyclosporine (Neoral; CsA) + MMF. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function (DGF). Patients were followed-up for 3 years., Results: The results at 3 years corroborate and extend the findings of the 2-year results. Patients with DGF treated with TAC+MMF experienced an increase in 3-year allograft survival compared with patients receiving CsA+MMF (84.1% vs. 49.9%, P=0.02). Patients randomized to either treatment arm containing TAC exhibited numerically superior kidney function when compared with CsA. During the 3 years, new-onset insulin dependence occurred in 6, 3, and 11 patients in the TAC+MMF, CsA+MMF, and TAC+AZA treatment arms, respectively. Furthermore, patients randomized to TAC+MMF received significantly lower doses of MMF as compared with those who received CsA+MMF., Conclusion: All three immunosuppressive regimens provided excellent safety and efficacy. However, the best results overall were achieved with TAC+MMF. The combination may provide particular benefit to kidney allograft recipients with DGF. In patients who experienced DGF, graft survival was better at 3 years in those patients receiving TAC in combination with either MMF or AZA as compared with the patients receiving CsA with MMF.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results